Literature DB >> 356983

5-fluorouracil, methyl-CCNU, adriamycin, and mitomycin C in the treatment of advanced gastric cancer.

P A Bunn, J L Nugent, D C Ihde, M H Cohen, J L Eddy, J D Minna.   

Abstract

Eighteen previously untreated patients with advanced nonresectable adenocarcinoma of the stomach were treated with a four-drug regimen consisting of 5-fluorouracil, methyl-CCNU, adriamycin, and mitomycin C. Objective responses occurred in only two patients (11%); the majority of patients had stable disease for greater than or equal to 8 weeks (61%). The median survival of 27 weeks was similar to that reported in other combination chemotherapy trials. Numerous staging and restaging procedures and strict response criteria were utilized and each was evaluated for its effectiveness in following responses. None of these parameters was useful for evaluating response of intra-abdominal tumor. We conclude that this four-drug combination is no better than previously described two-drug regimens.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 356983

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


  4 in total

1.  Combination chemotherapy enhances survival of patients with unresectable gastric cancer.

Authors:  T Kano; Y Hiramoto; Y Abe; T Notsuka; H Masuda; R Tamada; R Kumashiro; K Inokuchi
Journal:  Jpn J Surg       Date:  1983-09

Review 2.  Update in cancer chemotherapy: gastrointestinal cancer, cancer of the stomach and carcinoid tumors.

Authors:  J C Wright
Journal:  J Natl Med Assoc       Date:  1986-07       Impact factor: 1.798

3.  5-fluorouracil, adriamycin, and BCNU (FAB) combination chemotherapy for advanced gastric cancer.

Authors:  M Lopez; C F Perno; L Di Lauro; P Papaldo
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

4.  Late results of postoperative long term cancer chemotherapy for advanced carcinoma of the stomach.

Authors:  T Kano; R Kumashiro; R Tamada; Y Kodama; K Inokuchi
Journal:  Jpn J Surg       Date:  1981
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.